TMED7 Inhibitors
TMED7 inhibitors consist of an array of chemical compounds that target different aspects of intracellular trafficking and organelle function, indirectly leading to the inhibition of TMED7. Some compounds disrupt the structure and function of the Golgi apparatus. By blocking vesicular transport, these agents hinder the proper trafficking of TMED7, which cycles between the Golgi and the endoplasmic reticulum (ER), a critical process for its function. Similarly, chemicals that alter intracellular ion gradients and affect microtubule stability interfere with vesicle acidification and maturation or with the physical transport pathways that TMED7 relies upon for its role within the secretory pathway. The intricate balance of these processes is crucial for TMED7's activity, and thus their disruption leads to an indirect inhibition of TMED7's function.
Additionally, the protein's activity is contingent upon the precise coordination of vesicle trafficking and protein glycosylation within the cell. Inhibitors which block N-linked glycosylation affect the stability and transport of TMED7 by preventing its proper folding. Others target the GTPase activity of key molecules and disrupt trafficking between endosomes and the trans-Golgi network, respectively. The impact on TMED7 is further compounded by agents which can influence the extracellular matrix remodeling, and which inhibit vesicle fusion, both essential for the external environment required for TMED7's trafficking function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
This compound disrupts the structure and function of the Golgi apparatus, leading to a blockade of vesicular transport and indirectly inhibiting TMED7 which is involved in trafficking and cycling between the Golgi and the ER. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that alters intracellular ion gradients, particularly sodium and hydrogen ions, affecting vesicle acidification and maturation, thus potentially impacting TMED7's role in vesicular trafficking processes. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Inhibits N-linked glycosylation in the ER, thereby affecting the proper folding and function of TMED7, as it is a transmembrane protein that may require glycosylation for its stability and transport. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Specifically inhibits the Golgi BFA resistance factor 1 (GBF1), a GEF for the small GTPase ARF1, consequently affecting vesicular trafficking and indirectly inhibiting the function of TMED7. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Destabilizes microtubules, thereby interfering with vesicle transport processes that are essential for the proper functioning of TMED7 in the secretory pathway. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A small molecule inhibitor of the GTPase activity of dynamin, it disrupts endocytosis and vesicle trafficking, pathways in which TMED7 is potentially involved. | ||||||
Exo2 | 304684-77-3 | sc-215011 sc-215011A | 5 mg 25 mg | $89.00 $288.00 | 1 | |
A small molecule that disrupts the trafficking between endosomes and the trans-Golgi network, potentially influencing TMED7's role in vesicular transport. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $77.00 $270.00 | 55 | |
A broad-spectrum matrix metalloproteinase inhibitor that can affect the extracellular matrix remodeling, potentially impacting the external environment that TMED7 requires for its function in trafficking. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
By increasing the pH of intracellular organelles, it affects vesicle maturation and trafficking, thus indirectly impacting the functional role of TMED7 in these processes. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A V-ATPase inhibitor that prevents acidification of organelles, affecting protein trafficking and potentially inhibiting TMED7's function within this pathway. | ||||||